A comparison of allografting with autografting for newly diagnosed myeloma

Benedetto Bruno, Marcello Rotta, Francesca Patriarca, Nicola Mordini, Bernardino Allione, Fabrizio Carnevale-Schianca, Luisa Giaccone, Roberto Sorasio, Paola Omedè, Ileana Baldi, Sara Bringhen, Massimo Massaia, Massimo Aglietta, Alessandro Levis, Andrea Gallamini, Renato Fanin, Antonio Palumbo, Rainer Storb, Giovannino Ciccone, Mario Boccadoro

Research output: Contribution to journalArticle

398 Citations (Scopus)

Abstract

Background: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. Methods: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. Results: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P

Original languageEnglish
Pages (from-to)1110-1120
Number of pages11
JournalNew England Journal of Medicine
Volume356
Issue number11
DOIs
Publication statusPublished - Mar 15 2007

Fingerprint

Autologous Transplantation
Homologous Transplantation
Siblings
Autografts
Melphalan
Stem Cells
Disease-Free Survival
Allografts
Survival
Mortality
Whole-Body Irradiation
Vincristine
Clinical Protocols
Hematopoietic Stem Cells
Multiple Myeloma
Doxorubicin
Dexamethasone
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., ... Boccadoro, M. (2007). A comparison of allografting with autografting for newly diagnosed myeloma. New England Journal of Medicine, 356(11), 1110-1120. https://doi.org/10.1056/NEJMoa065464

A comparison of allografting with autografting for newly diagnosed myeloma. / Bruno, Benedetto; Rotta, Marcello; Patriarca, Francesca; Mordini, Nicola; Allione, Bernardino; Carnevale-Schianca, Fabrizio; Giaccone, Luisa; Sorasio, Roberto; Omedè, Paola; Baldi, Ileana; Bringhen, Sara; Massaia, Massimo; Aglietta, Massimo; Levis, Alessandro; Gallamini, Andrea; Fanin, Renato; Palumbo, Antonio; Storb, Rainer; Ciccone, Giovannino; Boccadoro, Mario.

In: New England Journal of Medicine, Vol. 356, No. 11, 15.03.2007, p. 1110-1120.

Research output: Contribution to journalArticle

Bruno, B, Rotta, M, Patriarca, F, Mordini, N, Allione, B, Carnevale-Schianca, F, Giaccone, L, Sorasio, R, Omedè, P, Baldi, I, Bringhen, S, Massaia, M, Aglietta, M, Levis, A, Gallamini, A, Fanin, R, Palumbo, A, Storb, R, Ciccone, G & Boccadoro, M 2007, 'A comparison of allografting with autografting for newly diagnosed myeloma', New England Journal of Medicine, vol. 356, no. 11, pp. 1110-1120. https://doi.org/10.1056/NEJMoa065464
Bruno, Benedetto ; Rotta, Marcello ; Patriarca, Francesca ; Mordini, Nicola ; Allione, Bernardino ; Carnevale-Schianca, Fabrizio ; Giaccone, Luisa ; Sorasio, Roberto ; Omedè, Paola ; Baldi, Ileana ; Bringhen, Sara ; Massaia, Massimo ; Aglietta, Massimo ; Levis, Alessandro ; Gallamini, Andrea ; Fanin, Renato ; Palumbo, Antonio ; Storb, Rainer ; Ciccone, Giovannino ; Boccadoro, Mario. / A comparison of allografting with autografting for newly diagnosed myeloma. In: New England Journal of Medicine. 2007 ; Vol. 356, No. 11. pp. 1110-1120.
@article{bef953017f7a41138daed96d7d5b6603,
title = "A comparison of allografting with autografting for newly diagnosed myeloma",
abstract = "Background: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. Methods: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. Results: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43{\%} vs. 7{\%}, P",
author = "Benedetto Bruno and Marcello Rotta and Francesca Patriarca and Nicola Mordini and Bernardino Allione and Fabrizio Carnevale-Schianca and Luisa Giaccone and Roberto Sorasio and Paola Omed{\`e} and Ileana Baldi and Sara Bringhen and Massimo Massaia and Massimo Aglietta and Alessandro Levis and Andrea Gallamini and Renato Fanin and Antonio Palumbo and Rainer Storb and Giovannino Ciccone and Mario Boccadoro",
year = "2007",
month = "3",
day = "15",
doi = "10.1056/NEJMoa065464",
language = "English",
volume = "356",
pages = "1110--1120",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - A comparison of allografting with autografting for newly diagnosed myeloma

AU - Bruno, Benedetto

AU - Rotta, Marcello

AU - Patriarca, Francesca

AU - Mordini, Nicola

AU - Allione, Bernardino

AU - Carnevale-Schianca, Fabrizio

AU - Giaccone, Luisa

AU - Sorasio, Roberto

AU - Omedè, Paola

AU - Baldi, Ileana

AU - Bringhen, Sara

AU - Massaia, Massimo

AU - Aglietta, Massimo

AU - Levis, Alessandro

AU - Gallamini, Andrea

AU - Fanin, Renato

AU - Palumbo, Antonio

AU - Storb, Rainer

AU - Ciccone, Giovannino

AU - Boccadoro, Mario

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Background: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. Methods: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. Results: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P

AB - Background: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. Methods: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. Results: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P

UR - http://www.scopus.com/inward/record.url?scp=33947197286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947197286&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa065464

DO - 10.1056/NEJMoa065464

M3 - Article

C2 - 17360989

AN - SCOPUS:33947197286

VL - 356

SP - 1110

EP - 1120

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -